SILtuximab in Viral ARds (SILVAR) Study
Stopped The REMAP-CAP and RECOVERY substudy results appear to support the survival benefit of tocilizumab in corticosteroid-treated or untreated patients with critically ill COVID-19-associated ARDS.
Conditions
- Acute Respiratory Distress Syndrome
- Lung Diseases
- Pneumonia
- Respiratory Tract Infections
- Respiratory Tract Disease
Interventions
- DRUG: Siltuximab
- OTHER: Normal Saline
Sponsor
RECORDATI GROUP
Collaborators